Literature DB >> 18998050

Successful cord blood transplantation for mycosis fungoides.

Takuya Fukushima1, Kensuke Horio2, Emi Matsuo2, Daisuke Imanishi2, Reishi Yamasaki2, Hideki Tsushima2, Yoshitaka Imaizumi2, Koichi Ohshima3, Tomoko Hata2, Shinichiro Yoshida4, Yasushi Miyazaki2, Masao Tomonaga2.   

Abstract

A 26-year-old female diagnosed as mycosis fungoides (MF, clinical stage IV) was treated with single-agent chemotherapy, multi-drug chemotherapy and unrelated bone marrow transplantation with reduced-intensity conditioning (engraftment failure), resulting in failure. Unrelated cord blood transplantation (CBT) as second transplantation following myeloablative conditioning brought complete remission (CR), but relapse of MF occurred 3 months after transplantation. However, discontinuation of immune suppressant led to the regression of MF regions and to second CR that continued for more than 23 months. This is the first report of successful CBT for MF, suggesting the graft-versus-MF effect in a setting of CBT.

Entities:  

Mesh：

Year:  2008        PMID： 18998050     DOI： 10.1007/s12185-008-0190-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  10 in total

1.  Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect.

Authors:  R K Burt; J Guitart; A Traynor; C Link; S Rosen; T Pandolfino; T M Kuzel
Journal:  Bone Marrow Transplant       Date:  2000-01       Impact factor: 5.483

Review 2.  Mycosis fungoides and Sezary syndrome.

Authors:  E Diamandidou; P R Cohen; R Kurzrock
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

3.  T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement.

Authors:  E Olavarria; F Child; A Woolford; S J Whittaker; J G Davis; C McDonald; S Chilcott; M Spittle; R J Grieve; S Stewart; J F Apperley; R Russell-Jones
Journal:  Br J Haematol       Date:  2001-09       Impact factor: 6.998

4.  Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides.

Authors:  Arturo Molina; Jasmine Zain; Daniel A Arber; Maria Angelopolou; Margaret O'Donnell; Joyce Murata-Collins; Stephen J Forman; Auayporn Nademanee
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

5.  Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen.

Authors:  Satoshi Takahashi; Jun Ooi; Akira Tomonari; Takaaki Konuma; Nobuhiro Tsukada; Maki Oiwa-Monna; Kenji Fukuno; Michihiro Uchiyama; Kashiya Takasugi; Tohru Iseki; Arinobu Tojo; Takuhiro Yamaguchi; Shigetaka Asano
Journal:  Blood       Date:  2006-10-12       Impact factor: 22.113

6.  Autologous bone marrow transplantation for advanced stage mycosis fungoides.

Authors:  R D Bigler; P Crilley; B Micaily; L W Brady; D Topolsky; S Bulova; E C Vonderheid; I Brodsky
Journal:  Bone Marrow Transplant       Date:  1991-02       Impact factor: 5.483

Review 7.  Mycosis fungoides and the Sézary syndrome.

Authors:  Y H Kim; R T Hoppe
Journal:  Semin Oncol       Date:  1999-06       Impact factor: 4.929

8.  Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources.

Authors:  V Rocha; J E Wagner; K A Sobocinski; J P Klein; M J Zhang; M M Horowitz; E Gluckman
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

9.  Treatment of advanced mycosis fungoides by allogeneic stem-cell transplantation with a nonmyeloablative regimen.

Authors:  D Soligo; A Ibatici; E Berti; P Morandi; E Longhi; L Venegoni; M Corbellino; C Annaloro; L Robbiolo; A Della Volpe; E Alessi; G Lambertenghi Deliliers
Journal:  Bone Marrow Transplant       Date:  2003-04       Impact factor: 5.483

10.  Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation.

Authors:  R J Jones; R F Ambinder; S Piantadosi; G W Santos
Journal:  Blood       Date:  1991-02-01       Impact factor: 22.113
  10 in total
  4 in total

1.  Feasibility of cord blood transplantation in chemosensitive adult T-cell leukemia/lymphoma: a retrospective analysis of the Nagasaki Transplantation Network.

Authors:  Takuya Fukushima; Hidehiro Itonaga; Yukiyoshi Moriuchi; Shinichiro Yoshida; Jun Taguchi; Yoshitaka Imaizumi; Daisuke Imanishi; Hideki Tsushima; Yasushi Sawayama; Emi Matsuo; Tomoko Hata; Yasushi Miyazaki
Journal:  Int J Hematol       Date:  2013-03-13       Impact factor: 2.490

2.  Reduced-intensity conditioning followed by cord blood transplantation in a patient with refractory folliculotropic mycosis fungoides.

Authors:  Takashi Nakaike; Koji Kato; Seido Oku; Masayasu Hayashi; Yoshikane Kikushige; Mika Kuroiwa; Katsuto Takenaka; Hiromi Iwasaki; Toshihiro Miyamoto; Takanori Teshima; Koichi Ohshima; Koichi Akashi
Journal:  Int J Hematol       Date:  2013-08-14       Impact factor: 2.490

3.  Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.

Authors:  Janet Y Li; Steven Horwitz; Alison Moskowitz; Patricia L Myskowski; Melissa Pulitzer; Christiane Querfeld
Journal:  Cancer Manag Res       Date:  2012-03-12       Impact factor: 3.989

4.  Skin Recurrence of Transformed Mycosis Fungoides Postumbilical Cord Blood Transplant despite Complete Donor Chimerism.

Authors:  Rahul Pawar; Anup Kasi Loknath Kumar; Janet Woodroof; Wei Cui; Joseph McGuirk; Sunil Abhyankar; Sid Ganguly; Anurag Singh; Tara Lin; Omar Aljitawi
Journal:  Case Rep Hematol       Date:  2014-12-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.